ATTR-CM Patient Education and Shared Decision-Making

Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026

Key Takeaways

• Education should make clear that ATTR-CM is chronic and progressive and that disease-modifying therapy slows progression rather than curing the disease.
• Adherence and long-term persistence are part of the conversation because benefit depends on sustained treatment over time.
• Shared decision-making applies to starting and continuing therapy, defining goals of care, and weighing cost and access.
• Hereditary disease adds a family dimension, including counseling and cascade screening for at-risk relatives.

Education Starts with What the Disease Is and Is Not

Useful shared decision-making depends on an accurate mental model of the disease. Patients benefit from understanding that ATTR-CM is a chronic, progressive condition and that current disease-modifying therapy is intended to slow progression rather than reverse established damage or cure the disease. Setting that expectation early prevents two common misunderstandings: that treatment will restore prior function, and that a stable period means the disease is gone. When framed accurately, education supports realistic expectations about therapy and its role in slowing disease progression over time.

Why Adherence and Persistence Are Part of the Conversation

Because treatment benefit depends on sustained exposure over time, staying on therapy matters, and that makes adherence and persistence legitimate topics for the patient conversation rather than afterthoughts. Real-world data on treated patients show that persistence can be high, but they shouldn’t be read to mean persistence is effortless for everyone; access, cost, follow-up complexity, and tolerability can all interrupt it. Discussing these barriers openly—and planning for them—is part of education.

Shared Decision-Making About Starting and Continuing Therapy

Shared decision-making in ATTR-CM isn't a single moment but a recurring process across the disease course. Decisions about whether to start therapy, whether to continue it as the disease evolves, and how aggressively to manage symptoms should reflect the patient's goals, values, and circumstances alongside the clinical evidence. Eliciting what matters most to the patient—independence, symptom relief, time, or avoiding burden—lets the team align treatment intensity and monitoring cadence with those goals, and it keeps decisions revisitable as the situation changes. This collaborative approach is supported by coordinated care through experienced amyloidosis centers and a stable long-term follow-up relationship.

Family Implications When the Disease Is Hereditary

When ATTR-CM is hereditary, education extends beyond the patient to the family. Patients should understand that a hereditary diagnosis has implications for relatives and that genetic counseling and cascade screening may be appropriate, whereas wild-type ATTR-CM isn’t inherited and doesn’t confer inherited risk to relatives. Communicating this clearly helps patients make informed choices about sharing information with family members and supports relatives in deciding whether predictive testing is right for them. The process should include appropriate genetic counseling and discussion of predictive testing for at-risk relatives.

Practical Education and Decision Checklist

In a shared-decision conversation, confirm the patient understands:

• That ATTR-CM is chronic and progressive and that therapy slows rather than cures it
• Why staying on therapy and keeping follow-up appointments matters
• What barriers (cost, access, tolerability) might interrupt treatment and the plan for them
• What goals matter most to them and how those shape treatment intensity
• If hereditary, what the diagnosis means for relatives and what counseling is available

Clinical Decision Point

The recurring decision isn't only what to prescribe but whether the patient and clinician share an accurate understanding of the disease and a common set of goals. When education has established that therapy slows rather than cures and when the patient's priorities are explicit, decisions about starting, continuing, or adjusting treatment become collaborative and revisitable, and adherence support, cost navigation, and family counseling fall naturally into the same conversation.

Frequently Asked Questions

Related Reading

Part of the Spotlight On ATTR-CM resource center.

Outcomes and Burden

• Patient Burden in ATTR-CM
• Prognostic Indicators in ATTR-CM
• Hospitalization Triggers in ATTR-CM

Next Clinical Decision

• ATTR-CM Clinical Management
• Cost and Access Management in ATTR-CM

See the Evidence

• Primary Research in ATTR-CM

References:

1. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
2. Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
3. Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
4. Patient Perspectives on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Attributes. Cardiology and Therapy

This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.